Capecitabine (C) and bevacizumab (B) for nonresectable metastatic colorectal cancer (mCRC) patients: Results from phase II AIO 0105 trial.
Albrecht Kretzschmar(Roche (Switzerland)), Dirk Arnold(Asklepios Klinik Altona), D. Behringer, Thomas Wolff(University of Basel), Andreas Kirsch, E. Kettner(University Hospital Magdeburg), S. Hegewisch-Becker(HOPE Clinic), J. Zimber, K.-H. Pflüger, Nicolas Ziegenhagen
Cited by 0
Related Papers
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.3k
Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2016|1.1k